Kiniksa Pharmaceuticals International PlcKNSA
Price$75.22Intrinsic value$64.0715% below price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $754M+78.2% YoYTTM through 31 Mar 2026
Net Income $73.1MTTM through 31 Mar 2026
Free Cash Flow $164.2MTTM through 31 Mar 2026

Margins

Current
EBITDA Margin12.6%
Operating Margin13.7%
Net Margin9.7%

Returns

12.1%ROE
8.9%ROA
17.6%ROIC

Balance Sheet Health

Debt / Equity0.00x
Current Ratio3.79x
Net Debt-$468.1Mnet cash position
Cash & Equivalents$190M

Quality Metrics

Altman Z-Score17.81
Piotroski F-Score6 / 9
FCF Margin21.8%
Rule of 4053.6
Earnings-Beat Rate25.0%

Multi-Year Trend

Revenue
'22'23'24'25
FY2025: $677.6M
Diluted EPS$0.91TTM
'19'20'21'22'23'24'25
FY2025: $0.75

Dividend

No dividend

Capital Allocation

R&D Spend$105M
Capex Intensity0.2%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.